

09/871183

Search results

Refine Search

Your wildcard search against 10000 terms has yielded the results below.

Your result set for the last L# is incomplete.

The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

Search Results -

Terms	Documents
(transcomplementary or trans near complementary or trans near complement\$) near5 vector\$ and suicide near5 gene\$ and separate near5 packaging	0

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L10

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, May 05, 2004 [Printable Copy](#) [Create Case](#)

Set Name	Query	Hit Count	Set Name result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L10	(transcomplementary or trans near complementary or trans near complement\$) near5 vector\$ and suicide near5 gene\$ and separate near5 packaging	0	L10
L9	L8 and sodium near iodide	2	L9
L8	(transcomplementary or trans near complementary or trans near complement\$) near5 vector\$ and suicide near5 gene\$	19	L8
L7	l4 and suicide near5 gene\$	9	L7
L6	"AVC2.TK"	2	L6
L5	L4 and separate\$ near5 packaging	0	L5
	(transcomplementary or trans near complementary or trans near		

<u>L4</u>	complement\$) near5 vector and (E1 and E4)	48	<u>L4</u>
<u>L3</u>	(transcomplementary or trans near complementary or trans near complement\$) near5 vector near5 (E1 and E4)	4	<u>L3</u>
<u>L2</u>	L1 and (transcomplementary or trans near complementary)	22	<u>L2</u>
<u>L1</u>	adenovir\$ near5 vector\$	16047	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 48 of 48 returned.**

-
- ☐ 1. [20040063203](#). 28 Oct 03. 01 Apr 04. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough, Douglas E., et al. 435/369; 435/456 C12N005/08 C12N015/861.
-
- ☐ 2. [20030224404](#). 24 Feb 03. 04 Dec 03. High throughput directed evolution of nucleic acids by rational mutagenesis. Vega, Manuel, et al. 435/6; 435/320.1 435/325 435/69.1 435/91.2 530/350 536/23.1 C12Q001/68 C07H021/02 C07H021/04 C12P019/34 C12P021/02 C12N005/06.
-
- ☐ 3. [20030203488](#). 19 Mar 01. 30 Oct 03. Viral vectors and line for gene therapy. Mehtali, Majid, et al. 435/456; 435/235.1 C12N015/86 C12N007/00.
-
- ☐ 4. [20030203480](#). 30 Apr 03. 30 Oct 03. Method of preparing a eukaryotic viral vector. Kovesdi, Imre, et al. 435/320.1; 435/235.1 435/456 C12N015/861 C12N007/00.
-
- ☐ 5. [20030192066](#). 28 May 02. 09 Oct 03. Minimal adenoviral vector. Zhang, Wei-Wei, et al. 800/8; 424/93.2 435/235.1 435/320.1 435/456 536/23.2 800/21 A01K067/00 C07H021/04 A61K048/00 C12N015/861 C12N007/00.
-
- ☐ 6. [20030170885](#). 19 Dec 00. 11 Sep 03. Defective adenoviruses and corresponding complementation lines. Imler, Jean-Luc, et al. 435/320.1; 424/93.21 435/235.1 A61K048/00 C12N007/01 C12N015/861.
-
- ☐ 7. [20030165462](#). 05 Oct 01. 04 Sep 03. Deleted adenovirus vectors and methods of making and administering the same. Amalfitano, Andrea, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N015/861 C12N007/00.
-
- ☐ 8. [20030138412](#). 27 Jun 02. 24 Jul 03. Inhibition of tumor growth and metastasis by N5 gene. Goodrich, David W., et al. 424/93.21; 435/7.23 514/44 A61K048/00 G01N033/574.
-
- ☐ 9. [20030108521](#). 30 May 02. 12 Jun 03. Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization. Calatrava, Manuel Rosa. 424/93.2; 424/186.1 435/235.1 435/320.1 435/325 435/456 435/69.3 530/350 536/23.72 A61K048/00 A61K039/12 C07H021/04 C12P021/02 C12N005/06 C07K014/075 C12N007/00 C12N015/861.
-
- ☐ 10. [20030099615](#). 19 Jul 02. 29 May 03. Porcine adenovirus E1 and E4 regions. Tikoo, Suresh K.. 424/93.2; 435/235.1 435/456 514/44 A61K048/00 C12N015/86 C12N007/00.
-
- ☐ 11. [20030096240](#). 12 Sep 01. 22 May 03. Genomic organization of mouse and human sGC. Murad, Ferid, et al. 435/6; 435/199 435/320.1 435/325 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/22 C12P021/02 C12N005/06.
-
- ☐ 12. [20030087438](#). 02 Nov 01. 08 May 03. E1-revertant-free adenoviral composition. Brough, Douglas E., et al. 435/456; 435/235.1 435/239 A61K048/00 C12N015/861 C12N007/02 C12N007/00.
-
- ☐ 13. [20030054553](#). 23 Jul 01. 20 Mar 03. Adenovector complementing cells. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/00 C12N005/08.
-

-
- ☐ 14. 20030040100. 23 Jul 01. 27 Feb 03. Cell for the propagation of adenoviral vectors. Brough, Douglas E., et al. 435/235.1; 435/239 435/325 536/23.72 536/24.1 C12N007/02 C12N005/02 C07H021/04 C12N005/00 C12N007/01 C12N007/00.
-
- ☐ 15. 20030031649. 01 May 02. 13 Feb 03. Gene therapy to promote angiogenesis. Jan van Zonneveld, Anton, et al. 424/93.2; 435/456 A61K048/00 C12N015/869.
-
- ☐ 16. 20030017595. 23 Jul 01. 23 Jan 03. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/01 C12N005/08.
-
- ☐ 17. 20030008375. 27 Dec 01. 09 Jan 03. Methods for treating patients with adenoviral vectors. Zhang, Shuyuan, et al. 435/235.1; 435/239 435/456 C12N007/00 C12N007/02 C12N015/861.
-
- ☐ 18. 20020182723. 12 Jun 01. 05 Dec 02. AN IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS. Zhang, Shuyuan, et al. 435/320.1; 424/233.1 435/235.1 435/239 536/23.72 536/24.1 C12N007/01 C12N015/861 C07H021/04 A61K039/235.
-
- ☐ 19. 20020177215. 27 Dec 01. 28 Nov 02. Methods for producing purified adenoviral vectors. Zhang, Shuyuan, et al. 435/235.1; 435/239 435/456 C12N007/00 C12N007/02 C12N015/861.
-
- ☐ 20. 20020164802. 01 May 02. 07 Nov 02. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer. Fallaux, Frits J., et al. 435/456; 435/235.1 435/325 C12N015/861 C12N007/00 C12N005/06.
-
- ☐ 21. 20020142989. 22 May 02. 03 Oct 02. Oncolytic/immunogenic complementary-adenoviral vector system. Alemany, Ramon, et al. 514/44; 424/93.2 435/235.1 435/320.1 435/456 A61K048/00 C12N015/861.
-
- ☐ 22. 20020090717. 16 Jan 02. 11 Jul 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao, Guangping, et al. 435/239; 435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3 C12P021/04 C12N007/00 C12N007/01 C12N007/02 C12N005/08 C12N015/63 C12N015/85 C12N015/87 C12N015/86 C12N015/74.
-
- ☐ 23. 20020088014. 10 Oct 01. 04 Jul 02. Minimal adenovirus mediated recombinant vaccine. Fang, Xiangming, et al. 800/8; 435/235.1 435/320.1 435/456 A01K067/00 C12N015/867 C12N015/861 C12N007/00 C12N007/01.
-
- ☐ 24. 20020072120. 03 Aug 01. 13 Jun 02. Helper viruses for the preparation of recombinant viral vectors. Lusky, Monika, et al. 435/457; 435/235.1 435/325 435/69.1 C12N015/861 C12N007/00 C12P021/02 C12N005/06.
-
- ☐ 25. 20020042139. 31 May 01. 11 Apr 02. Methods and compositions for efficient gene transfer using transcomplementary vectors. Higginbotham, James N., et al. 435/457; C12N015/861.
-
- ☐ 26. 20010049136. 30 Nov 00. 06 Dec 01. Defective adenoviruses and corresponding complementation lines. Imler, Jean-Luc, et al. 435/320.1; 435/235.1 435/325 C12N015/861 C12N007/01 C12N005/06.
-

-
- ☐ 27. 6726907. 24 Apr 00; 27 Apr 04. Purified adenoviral compositions. Zhang; Shuyuan, et al. 424/93.2; 424/199.1 424/233.1 424/93.6 435/235.1 435/239 435/320.1. C12N007/00 C12N007/01 C12N015/861 A61K039/235 A61K048/00.
-
- ☐ 28. 6686200. 31 Aug 93; 03 Feb 04. Methods and compositions for the large scale production of recombinant adeno-associated virus. Dong; Jianyun, et al. 435/457; 435/235.1 435/320.1 435/325 435/366 435/455 435/456 435/69.1. C12N005/10 C12N015/861 C12N015/869 C12N015/63.
-
- ☐ 29. 6682929. 23 Jul 01; 27 Jan 04. Adenovector complementing cells. Brough; Douglas E., et al. 435/371; 435/320.1 435/325 435/366. C12N005/10 C12N015/861.
-
- ☐ 30. 6677156. 23 Jul 01; 13 Jan 04. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough; Douglas E., et al. 435/456; 435/320.1 435/325 435/366 435/367 435/368 435/369 435/370 435/371 435/372 435/372.1 435/372.2 435/373 435/455 435/457. C12N005/10 C12N015/63 C12N015/861.
-
- ☐ 31. 6489142. 25 Jan 01; 03 Dec 02. Methods and compositions for producing viral particles. Torrent; Christophe, et al. 435/69.1; 435/6 435/69.7 530/387.3 536/23.4 536/23.72. C12P021/06 C12P021/04 C12P021/08 C12Q001/68 C07H021/04.
-
- ☐ 32. 6479290. 27 Jan 00; 12 Nov 02. Chimeric adenoviral vectors. Mehtali; Majid, et al. 435/457; 435/235.1 435/320.1 435/455 435/91.33 435/91.4 536/23.1. C12N015/861 C12N015/86 C12N007/01 C12N015/09 C07H021/04.
-
- ☐ 33. 6475480. 06 Jul 99; 05 Nov 02. Use of adenoviral E4 reading frames to improve expression of a gene of interest. Mehtali; Majid, et al. 424/93.2; 435/235.1 435/320.1 435/440 435/455 435/456 514/44. A01N063/00 A01N043/04 C12N015/00 C12N007/00 C12N015/63.
-
- ☐ 34. 6403370. 10 Feb 97; 11 Jun 02. Oncolytic/immunogenic complementary-adenoviral vector system. Alemany; Ramon, et al. 435/320.1; 435/455 435/456 435/457. C12N015/861.
-
- ☐ 35. 6395519. 23 Apr 99; 28 May 02. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer. Fallaux; Frits J., et al. 435/91.42; 435/320.1 435/325 435/366 435/368 435/369 435/371 435/455 435/456 435/457 435/69.1 435/91.4. C12N005/10 C12N015/10 C12N015/63 C12N015/64 C12N015/861.
-
- ☐ 36. 6365394. 11 Sep 00; 02 Apr 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao; Guangping, et al. 435/239; 435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3. C12N007/00 C12N015/64 C12N007/02 C12P001/00.
-
- ☐ 37. 6350575. 02 May 00; 26 Feb 02. Helper viruses for the preparation of recombinant viral vectors. Lusky; Monika, et al. 435/5; 435/320.1 435/325 435/366 435/369 435/455 435/456 435/457 435/462 435/6 435/69.1 435/91.42. C12Q001/68 C12Q001/70 C12N015/861 C12N015/64 C12N005/10.
-
- ☐ 38. 6328958. 27 Aug 99; 11 Dec 01. Deleted adenovirus vectors and methods of making and administering the same. Amalfitano; Andrea, et al. 424/93.2; 435/320.1 435/455 435/91.4 514/44. A61K048/00 C12N015/88.
-

- ☐ 39. 6248514. 18 Aug 98; 19 Jun 01. Methods for measuring viral infectivity. Hutchins; Beth M., et al. 435/5; 435/3 435/4 435/7.1. C12Q001/70 C12Q003/00 C12Q001/00 G01N033/53.
-
- ☐ 40. 6204060. 31 Mar 97; 20 Mar 01. Viral vectors and line for gene therapy. Mehtali; Majid, et al. 435/456; 435/320.1 435/325 435/366 435/369 435/370. C12N015/86 C12N005/10 C12N015/63.
-
- ☐ 41. 6194191. 20 Nov 97; 27 Feb 01. Method for the production and purification of adenoviral vectors. Zhang; Shuyuan, et al. 435/239; 424/199.1 435/235.1 435/320.1. C12N007/02 C12N007/01.
-
- ☐ 42. 6133028. 30 Sep 99; 17 Oct 00. Defective adenoviruses and corresponding complementation lines. Imler; Jean-Luc, et al. 435/325; 424/93.2 435/320.1 435/456. C12N005/10 C12N015/34 C12N015/86.
-
- ☐ 43. 6066478. 09 Mar 98; 23 May 00. Helper viruses for preparing recombinant viral vectors. Lusky; Monika, et al. 435/91.41; 435/320.1 435/325 435/366 435/369 435/455 435/456 435/457 435/91.4 435/91.42 536/23.2 536/23.4 536/23.5 536/23.7. C12N015/64 C12N015/861 C12N005/10 C07H021/04.
-
- ☐ 44. 6040174. 26 Jan 95; 21 Mar 00. Defective adenoviruses and corresponding complementation lines. Imler; Jean-Luc, et al. 435/325; 424/93.2 435/320.1 435/456. C12N005/10 C12N015/86 C12N015/34.
-
- ☐ 45. 5994106. 26 Nov 96; 30 Nov 99. Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus. Kovesdi; Imre, et al. 435/91.4; 435/320.1 435/325 435/366 435/456. C12N005/10 C12N015/64 C12N015/86.
-
- ☐ 46. 5981225. 16 Apr 98; 09 Nov 99. Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same. Kochanek; Stefan, et al. 435/69.1; 435/320.1 435/456 435/457 536/23.5 536/23.72 536/24.1. C12P021/00 C12N007/01 C12N015/12 C12N015/33.
-
- ☐ 47. 5891690. 26 Apr 96; 06 Apr 99. Adenovirus E1-complementing cell lines. Massie; Bernard. 435/456; 435/235.1 435/371. C12N005/10 C12N015/86 C12N015/87.
-
- ☐ 48. EP 974668A. Novel vector used for gene transfer methods, e.g. gene therapy. LUSKY, M, et al. A01N043/04 A01N063/00 A61K031/70 A61K048/00 A61P003/10 A61P007/00 A61P009/00 A61P031/12 A61P031/18 A61P035/00 A61P037/06 C07K014/075 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N007/00 C12N007/01 C12N007/02 C12N015/00 C12N015/09 C12N015/34 C12N015/63 C12N015/86.
-

[Generate Collection](#)
[Print](#)

Terms	Documents
(transcomplementary or trans near complementary or trans near complement\$) near5 vector and (E1 and E4)	48

[Prev Page](#)
[Next Page](#)
[Go to Doc#](#)

PALM INTRANET

Day : Wednesday

Date: 5/5/2004

Time: 17:14:59

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.

Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Wednesday

Date: 5/5/2004

Time: 17:14:59

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)